Bicocca Open Archive

Logo unimib boa
CARBONE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.298
AS - Asia 7.326
EU - Europa 6.490
SA - Sud America 1.225
AF - Africa 131
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26.486
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.064
SG - Singapore 2.969
IT - Italia 1.695
CN - Cina 1.549
HK - Hong Kong 1.193
RU - Federazione Russa 1.158
BR - Brasile 981
DE - Germania 964
VN - Vietnam 800
SE - Svezia 719
IE - Irlanda 607
GB - Regno Unito 417
IN - India 156
CA - Canada 149
AT - Austria 141
FR - Francia 139
NL - Olanda 137
KR - Corea 134
UA - Ucraina 126
AR - Argentina 111
FI - Finlandia 109
TR - Turchia 104
ID - Indonesia 93
BD - Bangladesh 62
PL - Polonia 62
MX - Messico 55
ZA - Sudafrica 51
JP - Giappone 49
DK - Danimarca 46
EC - Ecuador 44
IQ - Iraq 40
ES - Italia 36
MY - Malesia 27
BE - Belgio 21
VE - Venezuela 20
CO - Colombia 19
PK - Pakistan 18
LT - Lituania 17
PT - Portogallo 17
PY - Paraguay 16
IL - Israele 14
MA - Marocco 14
RO - Romania 13
UZ - Uzbekistan 13
EG - Egitto 12
SA - Arabia Saudita 12
TW - Taiwan 12
CZ - Repubblica Ceca 11
DZ - Algeria 11
JO - Giordania 11
AE - Emirati Arabi Uniti 10
CH - Svizzera 10
AZ - Azerbaigian 9
CL - Cile 9
RS - Serbia 9
UY - Uruguay 9
KE - Kenya 8
PE - Perù 8
AU - Australia 7
BO - Bolivia 7
ET - Etiopia 7
SK - Slovacchia (Repubblica Slovacca) 7
CR - Costa Rica 6
GR - Grecia 6
IR - Iran 6
OM - Oman 6
HN - Honduras 5
JM - Giamaica 5
MM - Myanmar 5
PA - Panama 5
SN - Senegal 5
TH - Thailandia 5
TN - Tunisia 5
GH - Ghana 4
HU - Ungheria 4
LA - Repubblica Popolare Democratica del Laos 4
NP - Nepal 4
NZ - Nuova Zelanda 4
AL - Albania 3
NO - Norvegia 3
QA - Qatar 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
CG - Congo 2
GD - Grenada 2
GE - Georgia 2
GT - Guatemala 2
LU - Lussemburgo 2
MD - Moldavia 2
NG - Nigeria 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AO - Angola 1
BB - Barbados 1
BN - Brunei Darussalam 1
Totale 26.463
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.274
Singapore 1.601
Hong Kong 1.172
Ashburn 865
Frankfurt am Main 714
Fairfield 634
Dublin 586
Chandler 569
Milan 525
Woodbridge 486
Wilmington 477
Houston 390
New York 365
Santa Clara 330
Hefei 296
Dallas 295
Chicago 267
Seattle 264
Dearborn 252
Ho Chi Minh City 246
Cambridge 224
Los Angeles 224
Beijing 215
Princeton 215
Hanoi 187
London 150
Jacksonville 147
Shanghai 133
Buffalo 121
Seoul 121
Vienna 115
Nanjing 109
Lawrence 103
Moscow 103
Rome 103
Altamura 101
São Paulo 97
The Dalles 94
San Diego 73
Munich 69
Jakarta 63
Boardman 57
Helsinki 47
Warsaw 44
Council Bluffs 42
Nuremberg 42
Florence 41
Toronto 39
Monza 38
Rio de Janeiro 37
Tokyo 35
Turin 35
Stockholm 33
Guangzhou 31
Salt Lake City 31
Denver 30
Johannesburg 30
Andover 29
Lachine 29
Brooklyn 28
Haiphong 28
Phoenix 28
Lissone 27
Orem 27
Nanchang 26
Poplar 26
Boston 24
Columbus 24
Pune 24
Bari 23
Biên Hòa 22
Hangzhou 22
Changsha 21
Montreal 21
Ottawa 21
Tianjin 21
Atlanta 20
Brussels 20
Fremont 20
Mumbai 20
San Jose 20
Amsterdam 19
Quito 19
Da Nang 18
Genoa 18
Mexico City 18
Paris 18
Can Tho 17
Curitiba 17
Elk Grove Village 17
Guarulhos 17
Hebei 17
Bologna 16
Chennai 16
Düsseldorf 16
Hải Dương 16
Penang 16
Tampa 16
Turku 16
Bergamo 15
Totale 16.880
Salva come PNG Salva come JPEG
Nome #
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 518
The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis 411
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 385
Exploring the landscape of steatotic liver disease in the general US population 373
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 344
Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid 342
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 336
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 308
Autoimmune liver disease, autoimmunity and liver transplantation 306
Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation 291
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 288
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 272
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 271
Precision medicine in primary biliary cholangitis 270
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 269
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 268
Risk stratification in primary sclerosing cholangitis 268
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 266
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 262
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls 260
Endocrinology and Metabolic Diseases (Including Diabetes) 255
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 254
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 251
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 248
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 244
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 243
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 239
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 238
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 238
Autoimmune liver diseases 230
New Therapeutic Targets in Autoimmune Cholangiopathies 229
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 228
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 226
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 226
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 225
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 225
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 220
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 218
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 217
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 217
The challenges of primary biliary cholangitis: What is new and what needs to be done 213
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 209
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 206
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 205
Prognostic models in primary biliary cholangitis 203
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 198
Artificial Intelligence and liver: Opportunities and barriers 197
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 196
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 193
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 191
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 191
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 191
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency 187
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score 184
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 183
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 182
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 179
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 179
Artificial intelligence for precision medicine in autoimmune liver disease 176
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? 176
Genetics and epigenetics of primary biliary cirrhosis 175
Leptin attenuates ischemia-reperfusion injury in the rat liver 174
Comprehensive review of autoantibodies in patients with hyper-IgM syndrome 171
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 171
Hepatitis C virus and nonliver solid organ transplantation 170
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis 167
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 167
Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence? 166
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 166
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 164
Cell and organ bioengineering technology as applied to gastrointestinal diseases 163
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement 160
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study 160
How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology? 159
The immunobiology of female predominance in primary biliary cholangitis 158
Treatment of PBC-A step forward 157
Treatment discontinuation with peg-interferon: What to consider 157
Late acute liver allograft rejection; A study of its natural history and graft survival in the current era 156
Cost of illness of Primary Biliary Cholangitis - a population-based study 155
Geoepidemiology, Genetic and Environmental Risk Factors for PBC 154
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis 154
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 154
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)] 153
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 152
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort 150
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 149
The "gut microbiota" hypothesis in primary sclerosing cholangitis 148
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 146
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis 145
An update on novel pharmacological agents for primary sclerosing cholangitis 144
Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history 142
Liver Transplantation in the Clinic - Progress Made During the Last Three Decades 141
Reply to: "Fatigue and liver transplantation in patients with primary biliary cirrhosis" 141
The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study 138
Primary Biliary Cholangitis: advances in management and treatment of the disease 138
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation 137
An unusual endoscopic finding in a patient with melena: multiple gastric ulcers of regular shape 136
Solid organ transplantation. Has the promise been kept and the needs met? 135
LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis 134
Toward precision medicine in primary biliary cholangitis 134
Totale 20.959
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.443
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.443
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.709 0 0 0 0 0 261 283 312 237 213 207 196
2021/20221.871 193 187 214 143 141 142 54 105 79 145 170 298
2022/20232.934 333 740 266 252 264 370 126 130 222 76 83 72
2023/20242.687 71 111 108 258 293 580 383 76 156 173 93 385
2024/20256.364 445 717 389 347 506 216 322 290 669 813 685 965
2025/20267.393 1.534 958 1.171 1.569 1.502 659 0 0 0 0 0 0
Totale 27.326